Tenofovir led to undetectable hepatitis B virus (HBV) levels in 87% of
HIV positive coinfected individuals, and a similar proportion maintained
viral suppression over 6 years, according to a study described in the June 20 advance edition of Hepatology.
Due to overlapping transmission routes, many people are coinfected with
both HIV and HBV. Treatment guidelines recommend that such inidviduals
include in their antiretroviral regimen drugs that are active against
both viruses, such as tenofovir (Viread), emtricitabine (Emtriva), or
lamivudine (3TC or Epivir). Tenofovir and emtricitabine are included in
the Truvada, Atripla, Complera, and Stribild coformulations.
Anders Boyd from INSERM in Paris and fellow investigators with the
French HIV-HBV Cohort Study looked at hepatitis B outcomes among 111
HIV/HBV coinfected patients on antiretroviral therapy containing
tenofovir. Those also treated with entecavir (Baraclude) or pegylated
interferon were excluded.
Read more... Labels: HIV/HBV coinfection, tenofovir